Dastgheib v. Genentech

Genentech Prevails in Lucentis Research Litigation

November 9, 2006

PHILADELPHIA, PA – Rejecting the claims of the plaintiff, a nine-member federal jury determined that biotechnology giant, Genentech, did not owe any additional payments for research related to their macular degeneration treatment, Lucentis.  In the case, the plaintiff was an ophthalmologist involved with the drug’s research, who claimed she was entitled to additional payments based on her leadership in the development of the new treatment protocol. In official filings, the Securities and Exchange Commission placed a value of $1.4 to $4.1 billion on the plaintiff’s claims.

Partners Kenneth A. Gallo, Maria T. Vullo and Craig A. Benson (Paul Weiss) represented Genentech, Inc. in the proceedings.  Impact Trial’s Bill Weir provided trial presentation and technical assistance throughout the trial.

The case is Dastgheib v. Genentech, case number 2:04-cv-01283, in the U.S. District Court for the Eastern District of Pennsylvania.